Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included.
Name
10928_2020_9734_ReferencePDF.pdf
Size
2.86 MB
Format
Adobe PDF
Checksum (MD5)
0b54ff7b7aeb887f4f1c4b108f396374
Author(s)
Alaybeyoglu, Begum
Cheng, Ho W. (.
Doshi, Kshama A.
Makani, Vishruti
Stein, Andrew M.
Date Issued
February 8, 2021
Publisher
Springer US
Version
Author's final manuscript
Abstract
Abstract
Predictions for target engagement are often used to guide drug development. In particular, when selecting the recommended phase 2 dose of a drug that is very safe, and where good biomarkers for response may not exist (e.g. in immuno-oncology), a receptor occupancy prediction could even be the main determinant in justifying the approved dose, as was the case for atezolizumab. The underlying assumption in these models is that when the drug binds its target, it disrupts the interaction between the target and its endogenous ligand, thereby disrupting downstream signaling. However, the interaction between the target and its endogenous binding partner is almost never included in the model. In this work, we take a deeper look at the in vivo system where a drug binds to its target and disrupts the target’s interaction with an endogenous ligand. We derive two simple steady state inhibition metrics (SSIMs) for the system, which provides intuition for when the competition between drug and endogenous ligand should be taken into account for guiding drug development.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s10928-020-09734-9
